VIDA Partners With TeraRecon, Inc. for AI-Powered Lung Analysis

VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, announced a distribution agreement with TeraRecon, Inc., a leader in advanced visualization, artificial intelligence, image viewing, and post-processing. With this agreement, VIDA's LungPrint analysis will be available through TeraRecon's AI Interoperability platform, EnvoyAI, expanding the reach of VIDA's leading AI-powered pulmonary care solutions and creating an integrated physician experience. LungPrint Discovery offers fully automatic radiological metrics and unique, time-saving airway visualizations. By precisely quantifying lung characteristics in a chest CT scan, LungPrint helps providers detect COPD and other interstitial lung diseases earlier, often when debilitating symptoms have yet to occur. Early detection of chronic lung disease is reported to elongate life expectancies and reduce overall healthcare costs (Larsson, et.